Provided by Tiger Fintech (Singapore) Pte. Ltd.

PTC Therapeutics

49.53
-0.0200-0.04%
Post-market: 49.530.00000.00%16:41 EDT
Volume:593.75K
Turnover:29.44M
Market Cap:3.91B
PE:-10.48
High:50.07
Open:49.11
Low:48.09
Close:49.55
Loading ...

PTC Therapeutics price target lowered to $72 from $74 at JPMorgan

TIPRANKS
·
28 Feb

PTC Therapeutics: Strong Financial Performance and Strategic Partnerships Justify Buy Rating

TIPRANKS
·
28 Feb

PTC Therapeutics Inc (PTCT) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...

GuruFocus.com
·
28 Feb

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
28 Feb

PTC Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

PTC Therapeutics Exceeds 2024 Revenue Guidance

TIPRANKS
·
28 Feb

PTC Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

PTC Therapeutics Q4 2024 Adj EPS $(0.85) Misses $(0.66) Estimate, Sales $213.00M Miss $232.44M Estimate

Benzinga
·
28 Feb

PTC Therapeutics Q4 Product Revenue USD 154.706 Million

THOMSON REUTERS
·
28 Feb

PTC Therapeutics Inc Outlook 2025 Total REV Between $600 Mln and $800 Mln

THOMSON REUTERS
·
28 Feb

Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks
·
24 Feb

Hold Rating on PTC Therapeutics Amidst Mixed Outcomes for Vatiquinone in Friedreich’s Ataxia Treatment

TIPRANKS
·
19 Feb

PTC Therapeutics Says FDA Grants Priority Review to Vatiquinone NDA for Treating Friedreich's Ataxia; Shares Up Pre-Bell

MT Newswires Live
·
19 Feb

BRIEF-Ptc Therapeutics Announces FDA Acceptance And Priority Review For Vatiquinone NDA

Reuters
·
19 Feb

PTC Therapeutics Inc - Pdufa Target Action Date of Aug. 19, 2025

THOMSON REUTERS
·
19 Feb

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone Nda for the Treatment of Children and Adults With Friedreich's Ataxia

THOMSON REUTERS
·
19 Feb

PTC Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
19 Feb

RBC Capital Adjusts PTC Therapeutics Price Target to $63 From $60, Maintains Outperform Rating

MT Newswires Live
·
18 Feb

PTC Therapeutics Inc : RBC Raises Target Price to $63 From $60

THOMSON REUTERS
·
18 Feb

PTC Therapeutics price target raised to $45 from $32 at Citi

TIPRANKS
·
12 Feb